Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Gilead Research Scholars Program in Solid Tumors 2026 - Oncology News, Insights, Stories by OncoDaily
8+ hour, 18+ min ago (149+ words) Gilead Research Scholars Program in Solid Tumors 2026 Oncodaily Gilead Research Scholars Program in Solid Tumors 2026 The Gilead Research Scholars Program in Solid Tumors 2026 supports early-career investigators conducting independent basic or clinical research addressing unmet needs in breast, endometrial, ovarian, or…...
Patients??? voices vital to closing breast cancer care gaps
5+ hour, 30+ min ago (374+ words) By Teodoro B. Padilla Healthcare systems often measure success in numbers — beds filled, medicines dispensed, procedures performed. Yet behind every statistic is a patient whose lived experience reveals the gaps, struggles and moments of resilience that data alone cannot capture. Elevating…...
Endocrine Therapy for ESR1-Mutated Metastatic Breast Cancer
1+ day, 1+ hour ago (216+ words) In the first segment of this roundtable series, the panel discusses the current treatment landscape, how it has evolved with new approvals and data, ongoing trials, and what might be on the horizon for patients with ESR1-mutated disease in the…...
Beyond the First-Line for ESR1-Mutated Disease
1+ day, 1+ hour ago (273+ words) An expert panel moderated by Sara Nunnery, MD, of Tennessee Oncology, convened to discuss how they choose therapy beyond the first-line setting for patients with ESR1-mutated disease. Dr. Nunnery was joined by Nan Chen, MD, of the University of Chicago;…...
AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial
15+ hour, 40+ min ago (12+ words) firstwordpharma.com...
Breast cancer pill from AstraZeneca misses mark in pivotal trial
1+ day, 14+ hour ago (204+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
2+ day, 16+ hour ago (424+ words) Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow and is already approved for a narrower group of breast cancer patients. The setback lands on a pipeline already under scrutiny. Shares of…...
Alix and Ashtin Earle Recall the ‘Shock’ of BRCA Test Results After Mom’s Breast Cancer Diagnosis
2+ day, 14+ min ago (352+ words) Alix Earle and her sister, Ashtin, are urging women to take proactive control of their health after learning they both carry a BRCA gene mutation. The news arrived shortly after their mom, Alisa, was diagnosed with breast cancer in late…...
Biparatopic HER2 Targeting in Action: Anbenitamab???s Phase 3 Breakthrough
2+ day, 20+ hour ago (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....
Saidal, Roche sign partnership to localize breast cancer medicines production in Algeria
3+ day, 5+ hour ago (66+ words) aps.dz Saidal, Roche sign partnership to localize breast cancer medicines production in Algeria ALGIERS - Saidal Group signed on Thursday, in Algiers, a partnership agreement with the Swiss company "Roche" Algeria with a view to localizing the production of breast…...